Interleukin (IL)-25 is shown to potentiate type-2 immunity and contribute to chronic airway inflammation and remodeling in allergic airway diseases. However, the role of IL-25 in idiopathic pulmonary fibrosis (IPF), dominated by nonatopic type-2 immunity, still remains largely unclear. Herein, we detected the expression levels of IL-25 and IL-17BR (IL-25's receptor) by using lung tissue samples gained from IPF patients and normal subjects. Also, by directly intranasal (IN) instillation of IL-25 to mice, we examined the potential roles and mechanisms of IL-25 in the development of lung fibrosis. Furthermore, we tested whether IL-25 can directly activate human lung fibroblast by in vitro cell culture. Immunohistochemical, Western blot, and real-time reverse transcription-polymerase chain reaction (RT-PCR) showed that the mRNA and protein levels of IL-25 and IL-17BR are significantly higher in IPF patients when compared with normal controls. Intranasal instillation of IL-25 to mice markedly induces the expressions of alveolar IL-5 and IL-13.
Introduction
Idiopathic pulmonary fibrosis (IPF) is a well-known yet untreatable fibrotic lung disease with increasing morbidity and hospital admissions rates. [1] [2] [3] Usual interstitial pneumonia (UIP) is the histological features of IPF 4 ; however, the precise molecular event that initiates and maintains UIP is currently unknown. It has been shown that dysfunctional epithelium-derived profibrotic milieu drives the progress of fibrotic lesions. 5, 6 Unfortunately, the master switch hidden in the profibrotic milieu is still not well elucidated.
Interleukin (IL)-25, a newly discovered member of IL-17 cytokine family, is produced by disordered epithelial cells and innate immune cells. 7 It has been shown that IL-25 initiates a type-2 skewed immune response by excessive production of IL-4, IL-5, and IL-13, 7 which contributes to the pathogenesis of allergic airway diseases (AADs).
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Impact statement
Our work focused on alveolar epithelial cells (AECs)-derived type-2 cytokine (interleukin [IL]-25) in the pathogenesis of idiopathic pulmonary fibrosis (IPF). We showed that IL-25 and IL-17BR (IL-25's receptor) is upregulated in lung tissues (especially in AECs and lung fibroblasts) of IPF patients and contributes to lung fibrosis by directly activating lung fibroblasts and modulating epithelial-mesenchymal transition (EMT) of AECs. We suggest that IL-25 may be one of the master switches hidden in the milieu of abnormal epithelialmesenchymal crosstalk. Treatment targeting IL-25 may be the potential and novel method for IPF patients.
However, the potential role of IL-25 in allergenindependent lung inflammation and fibrosis driven by type-2 cytokine responses is not well interpreted. By using transgene mice, it was previously shown that IL-25 may mediate lung fibrosis by recruiting type-2 innate lymphoid cells (ILC2s). 11 However, the potential profibrotic role of IL-25 as a cytokine itself still remains unknown. Also, little is known about the direct modulatory role of IL-25 on alveolar epithelial cells (AECs) and lung fibroblasts (two major cellular serial killers for IPF). Herein, we reported IL-25 is upregulated in IPF lungs and hypothesized that the fibrotic role of IL-25 may be mediated by the activation of (IL-17BR) þ -AECs and (IL-17BR) þ -fibroblasts.
Materials and methods
Study subjects and samples
All human study protocols were approved by the Ethics Committee of Capital Medical University, Beijing, China. All patients signed the informed written consent. Fibrotic lung tissues were obtained from nine patients with IPF who received pulmonary transplantation or diagnostic videoassisted thoracoscopic surgery. The diagnosis of IPF was followed with the official American Thoracic Society/ European Respiratory Society/Japanese Respiratory Society/Latin American Thoracic Association (ATS/ERS/ JRS/ALAT) statement published in 2011. 2 Normal control lung tissues (n ¼ 6) were obtained from healthy lung explants remaining after transplantation.
Murine study protocols
Mature female BALB/C mice were purchased from Vital River Laboratories (Beijing, China). They were fed in pathogen-free conditions at the Animal Center of Capital Medical University. The Animal Care and Use Committee of Capital Medical University approved the study procedures. To directly examine the potential profibrotic role of IL-25, mice were anaesthetized with isoflurane gas (4%) and administered by daily intranasal (IN) injection of 2 lg of recombinant mouse IL-25 (mIL-25, R&D System, Minneapolis, MN, USA) in 50 lL of sterile saline from day 0 to day 7. Thereafter, mIL-25 was intranasally administrated every 2 days for another 24 days. Control mice were intranasally injected with 50 lL of sterile saline instead in the same time points. On days 3, 7, 19, and 31 after the first challenge of mIL-25 or saline, mice were sacrificed for Bronchoalveolar Lavage Fluid (BALF) and lung tissue collection. The procedure of mIL-25 in nonatopic mice airway inflammation and remodeling was also depicted elsewhere. 12 
Fibroblast cultures
The human embryonic lung fibroblasts (MRC-5) were purchased from American Type Culture Collection (Rockville, MD, USA). The detailed information is shown in the supporting materials. Cells were challenged with the recombinant human IL-25 (hIL-25; 1, 10, 100 ng/mL), human transforming growth factor (TGF)-b1 (10 ng/mL; both from R&D Systems), or both. The corresponding vehicles were used for control study. Thereafter, cell proliferation and RNAs expression assays were performed.
Histologic analysis
Human and murine lung biopsies were processed for histological analysis. The detailed procedure is shown in the supporting information. The simplified pathology score for fibrotic lesions was as below: grade 1, no fibrotic lesion; grade 2, occasional small interstitial fibrotic lesion; grade 3, moderate fibrotic lesions; and grade 4, continuous interalveolar fibrosis. At least 10 high-power fields of each slide were analyzed in a blind fashion by two independent experienced pathologists. 13 
Immunohistochemistry
Immunohistochemistry was used for detecting the expressions of IL-25, IL-17BR, collagen I, collagen III, fibronectin, connective tissue growth factor (CTGF), and fibroblast growth factor receptor 4 (FGFR4) in fibrotic lung tissues from IPF patients or murine model. The detailed procedure is shown in supplemental materials.
BALF collection and harvest of lung homogenate
BALF and lung homogenate were collected for detecting the expression of IL-5 and IL-13. The detailed information is shown in the supporting materials.
Lung collagen assay
The soluble collagen in murine lung tissues was determined by using the Sircol Collagen Assay Kit (Biocolor, Carrickfergus, UK), according to the producer's instructions.
Enzyme-linked immunosorbent assay
The BALF and lung homogenate concentrations of murine type-2 cytokines, IL-5 and IL-13, were measured by enzyme-linked immunosorbent assay (ELISA) as per the manufacturer's instructions of the detecting kits (R&D Systems).
Western blot
Western blot (WB) was used for detecting the expression levels of lung IL-25, IL-17RA, and IL-17RB. The detailed protocol is shown in the supporting materials.
Real-time RT-PCR
Reverse transcription-polymerase chain reaction (RT-PCR) was used to detect the mRNA expression levels of target genes in lung tissues or fibroblast. The detailed information is shown in the supporting materials.
Cell proliferation assay
Cell proliferation was measured by Cell Counting Kit-8 (CCK-8) (Solarbio) and EDU Imaging Kit (ThermoFisher) as per manufacturer's protocol.
Statistical analysis
All results were expressed as mean AE SEM. GraphPad Prism 5.0 (GraphPad Software, San Diego, CA, USA) was used for statistical analysis and figures drawing. Statistical significance of differences between two groups was determined by using independent Student's t test. Comparisons between multiple treatment groups were performed by analysis of variance (ANOVA, one-way or two-way, as appropriate) with Bonferroni post hoc test. Differences were considered significant at P value <.05.
Results
IL-25 and IL-17BR expression is upregulated in lung tissues of IPF patients
First, we showed a pattern of "UIP" in IPF lungs (Figure 1 
mIL-25 initiates the formation of alveolar type-2 cytokine milieu in vivo
Next, we tested whether IL-25 can drive the type-2 immunity in lung parenchyma in vivo. We showed that the 
mIL-25 induces significant lung inflammation and extensive lung fibrosis in mice
We showed that mice received mIL-25 develop significant and progressive lung inflammation (increased numbers of alveolar inflammatory cells and lymphoid follicles, Figure  S3 ) and fibrosis (Masson staining, Figure 3 ) from day 7, peaks at day 31, compared with saline control mice. Specifically, IL-25 can induce significant peribronchial fibrotic reaction. Although less extensive, IL-25 can also induce remarkable fibrosis of lung parenchyma as indicated by the dark blue staining in the distal airway and alveolar spaces. By contrast, the lung slide is stained with brown red color in mice with saline instillation. Whole soluble lung collagen assay further elucidated that mIL-25 notably enhances lung collagen deposition (Figure 3(j) ).
mIL-25 enhances a profibrotic milieu by acting on AECs and recruiting fibroblast
We next aimed to further explore the potential mechanisms that underlie IL-25's profibrotic role. We firstly showed that mIL-25 notably induces the expression of extracellular matrix proteins including collagen I, collagen III, and fibronectin at day 31 compared with saline control mice (Figure 4(a) to (f) ). The immunoreactivity for collagen I/III and fibronectin is not only limited to cells that resided in peribronchial/vascular areas but also significantly in injured AECs (Figure 4(a) to (f) ). Furthermore, we also showed that the immunoreactivity for CTGF (major in AECs) is significantly higher at day 31 in mice treated with mIL-25 than those treated with saline only (Figure 4 (g) and (h)). We also showed that fibroblast (FGFR4-positive cell) is recruited in the peribronchial areas following mIL-25 nasal inhalation compared with saline-treated mice (Figure 4(i) and (j) ). IgG-isotype control for immunohistochemical assay was shown in Figure S4 .
hIL-25 enhances proliferation of human lung fibroblast in vitro
We are interested in the pending topic that whether lung fibroblast is a direct cellular target for IL-25. As shown by ........................................................................................................................................................ .... Figure 5 (a), at as early as 24 h, both hIL-25 and TGF-b1 significantly increase the absorbance value, as compared with that in the vehicle control cells. However, hIL-25 plus TGF-b1 fails to induce further increase in the absorbance value ( Figure 5(a) and (b) ).
CCK-8 assay in
hIL-25 augments production of profibrotic genes in human lung fibroblast in vitro
Compared with vehicle-treated cells, both IL-25 and TGF-b1 induce a rapid and persistent increase in collagen I/III, fibronectin, a smooth muscle (a-SMA), CTGF, and tissue inhibitor of metalloproteinase (TIMP)-1 mRNA expression in fibroblasts ( Figure 6 ). By contrast, hIL-25 or TGF-b1 treatment initially facilitates the mRNA expressions of matrix metalloproteinase (MMP)-1 and MMP-9 but eventually reduces their expressions when compared with vehicle controls (Figure 6(g) and (h) ). However, no significant synergism is observed between hIL-25 and TGF-b1 in terms of mRNAs expression of these profibrotic genes.
Discussion
The role of IL-25 in developing type-2 immunity-mediated allergic airway inflammation and remodeling has been well demonstrated in human and murine models. [7] [8] [9] [10] The data presented here examined the potential role and mechanism of IL-25 in the context of nonallergen-driven fibrotic lung disease, i.e. IPF. We reported for the first time that IL-25/IL-25R axis is upregulated in injured AECs and lung fibroblasts that make up FFs. IL-25 exerts its profibrotic role by a hitherto unrecognized mechanism, i.e. by ......................................................................................................................................................... ... ............................................................................................................................................................... directly activating lung fibroblast and changing the phenotype of AECs.
By using immunohistochemical analysis, we found that both IL-25 and IL-17BR are markedly upregulated in injured AECs in FF of IPF lungs (Figure 1(f) and (h) ), indicating that AECs represent as both cellular source and target of IL-25. This is in accordance with the concept that believes IL-25 is major derived from epithelial cells. 14 Currently, numerous evidences support the hypothesis that repetitive cycles of alveolar epithelium injury and/or dysfunction drives the development of lung fibrosis by promoting the activation of lung fibroblast. 6, 15, 16 Herein, we suggest that injured AECs mediate abnormal epithelialmesenchymal cross talk by excessive secretion of IL-25 because we showed that IL-17BR (the receptor for IL-25) staining is also markedly localized in the fibroblasts with spindle appearance in the FF (Figure 1(f) and (h) ). This is also in keeping with a previous in vitro finding which showed that human primary lung fibroblasts constitutively express IL-17BR. 17 Collectively, our data support the notion that elevated IL-25/IL-17BR axis mediates epithelialmesenchymal interaction (i.e. epithelium-derived IL-25 may activate fibroblast by binding binds IL-17BR which is expressed on fibroblast) in the context of lung fibrosis.
In line with our study, Hams et al. found that BALF level of IL-25 was significantly increased in IPF patients (n ¼ 14). 11 Unexpectedly, Lee et al. in a recent relatively large cohort of patients with IPF (n ¼ 100) showed that BALF level of IL-25 is not different between normal controls and IPF group. 18 The reason for the discrepancy between these studies is currently unknown. We suggested that the expression level of IL-25 may vary depending on disease severity and different disease phenotypes of IPF (e.g. patients with rapid progressive course or slow rapid progressive course or acute exacerbation). We found that notably upregulated levels of IL-25 correlates with extensive fibrotic lesion (severe IPF) in lung tissues of IPF patients (Figure 1 ). However, Lee et al.'s study recruited mildto-moderate IPF patients with mean forced vital capacity % pred. at 75.0 (63.7-83.0). 18 Therefore, we suggest that large cohort with different phenotypes of IPF patients is needed to further confirm the expression levels of IL-25 and its relationship to IPF.
We also assessed whether IN delivery with IL-25 contributes to lung fibrosis in mice. The delivery methods for developing murine lung fibrosis model include intratracheal route, 19, 20 IN route, [21] [22] [23] oropharyngeal aspiration route, 24 and subcutaneous route. 25 We chose IN route because its simplicity, speed, and noninvasive nature. It was previously shown larger delivery volume and anesthesia can facilitate the relative distribution of the delivery agent to the lower respiratory tract (LRT). 26 Thus, in our study, IL-25 was dissolved in 50 lL of sterile saline, and mice were anaesthetized with isoflurane gas in order to allow sufficient access of IL-25 to LRT and lung parenchyma.
We reported that IN instillation with IL-25 initiates a local type-2 immunity skew by upregulating the expression of IL-5 and IL-13. As shown in Figure 2 , both BALF and lung IL-5 and IL-13 are rapidly induced by IL-25 IN instillation at day 3 and peak at day 7 (day 19 for lung IL-13) but all decrease to normal control level at day 31. By contrast, lung fibrosis induced by IL-25 develops at day 7 and gradually peaks at day 31 ( Figure 3 ). This suggests that IL-25 drives lung fibrosis initially in a type-2 immunity-dependent fashion, which supports the notion that the Th1/Th2 paradigm in favor of Th2 correlates with fibrotic diseases. 27 However, we hypothesize that with the progression of lung fibrosis, type-2 immunity may become dispensable and decreases to a relative low level because fibrotic lesions can self-propagate once (myo)fibroblast is fully activated and epithelial-mesenchymal interaction loop is well developed.
Most importantly, in our study, we hypothesize that IL-25 drives lung fibrosis by directly acting on injured AECs and fibroblast. First, both AECs and fibroblast express IL-17BR which binds with and respond to IL-25. Second, we found that following with IL-25 IN instillation, collagen I, collagen III, fibrobectin, and CTGF are not only induced in the areas of sub-bronchial epithelium but also induced in AECs in the distal areas (far away from large airways). This indicated that AECs starts to produce several mesenchymal markers in response to IL-25 ( Figure 4(b) , (d), (f), and (h)). Thus, we suggest that IL-25 may induce a process that mimics type-2 epithelial-mesenchymal transition (EMT) in vivo and promote AECs to change their phenotype in favor of profibrotic fashion. 28 This was also confirmed by a previous study which showed the CTGF is confined predominantly to the proliferating type-II AECs in IPF lungs detected by immunohistochemical analysis. 29 Third, we and previous study 30 showed that IL-25 IN instillation significantly increased the numbers of lung fibroblast in the lung mesenchymal areas (Figure 4(j) ). By in vitro cell culture, we reported for the first time that IL-25 notably potentiated the proliferations and several profibrotic gene expressions (including collagen I/III, fibronectin, CTGF, a-SMA, TIMP-1) of lung fibroblast (Figures 5 and  6 ). This indicates that IL-25 directly acts on lung fibroblast and may mediate lung fibrosis by augmenting activation/ differentiation of fibroblast and inducing a skewing in favor of antiprotease system (i.e. TIMP-1 is upregulated whereas MMP-9 is downregulated). It is well known that the impaired proteases and antiproteases balance is implicated in the pathogenesis of IPF. 31 Unexpectedly, we did not found a synergistic effect between IL-25 and TGF-b1, rather showed a somewhat antagonistic effect between them. This may be interpreted by the findings that TGFb1 markedly inhibited IL-17BR mRNA expression in fibroblast. 17 We also suggest that higher concentration of IL-25 may also counteract the proliferative effect of endogenous TGF-b1 because 10 ng/mL of IL-25 is more effective to promote the proliferation of lung fibroblast than 100 ng/mL at 72 h ( Figure 5(a) ). However, this needs further confirmative studies. Different from our studies, Hams et al. 11 showed that ILC2 depletion obviously inhibited lung collagen deposition induced by IL-25. These data indicate various cellular targets of IL-25.
In conclusion, our study extends the current understanding of IL-25' pathobiology beyond that of AADs. We reported that upregulated IL-25/IL-17BR axis contributes to lung fibrosis by promoting phenotype changes of AECs and activating fibroblast. However, we failed to assess the relationship between IL-25 and clinical features of IPF because of the small numbers of the cohort. Also, we did not examine whether IL-25 can directly induce EMT of AECs in vitro. The signaling pathways that underlie IL-25's effects on fibroblast are remained elusive. Thus, how IL-25 contributes to the pathogenesis of IPF should be further determined.
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